Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over

NCT03826628 is registered in ClinicalTrials.gov with Dermatology Specialties Limited Partnership as lead sponsor.

NCT NCT03826628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03826628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over
Lead sponsor
Dermatology Specialties Limited Partnership
Phase
Phase 2/3
Overall status
Completed
Start date
July 28, 2019
Completion date
September 1, 2022
Enrollment
107 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

facial angiofibroma, tuberous sclerosis